Werewolf Therapeutics Stock Probability of Future Stock Price Finishing Over 27.67
| HOWL Stock | USD 1.59 0.05 3.25% |
Werewolf |
Werewolf Therapeutics Target Price Odds to finish over 27.67
The tendency of Werewolf Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 27.67 or more in 90 days |
| 1.59 | 90 days | 27.67 | close to zero percent |
Based on a normal probability distribution, the odds of Werewolf Therapeutics to move over $ 27.67 or more in 90 days from now is close to zero percent (This Werewolf Therapeutics probability density function shows the probability of Werewolf Stock to fall within a particular range of prices over 90 days) . Probability of Werewolf Therapeutics price to stay between its current price of $ 1.59 and $ 27.67 at the end of the 90-day period is about 86.23 .
Given the investment horizon of 90 days Werewolf Therapeutics has a beta of 0.15. This usually indicates as returns on the market go up, Werewolf Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Werewolf Therapeutics will be expected to be much smaller as well. Additionally Werewolf Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Werewolf Therapeutics Price Density |
| Price |
Predictive Modules for Werewolf Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Werewolf Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Werewolf Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Werewolf Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Werewolf Therapeutics is not an exception. The market had few large corrections towards the Werewolf Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Werewolf Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Werewolf Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.15 | |
β | Beta against Dow Jones | 0.15 | |
σ | Overall volatility | 0.44 | |
Ir | Information ratio | -0.02 |
Werewolf Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Werewolf Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Werewolf Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Werewolf Therapeutics generated a negative expected return over the last 90 days | |
| Werewolf Therapeutics has high historical volatility and very poor performance | |
| Werewolf Therapeutics may become a speculative penny stock | |
| Werewolf Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 19.94 M. Net Loss for the year was (37.37 M) with loss before overhead, payroll, taxes, and interest of (37.36 M). | |
| Werewolf Therapeutics currently holds about 145.71 M in cash with (32.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.93, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 73.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Daniel Hicklin of 295500 shares of Werewolf Therapeutics subject to Rule 16b-3 |
Werewolf Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Werewolf Stock often depends not only on the future outlook of the current and potential Werewolf Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Werewolf Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 35.6 M | |
| Cash And Short Term Investments | 134.3 M |
Werewolf Therapeutics Technical Analysis
Werewolf Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Werewolf Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Werewolf Therapeutics. In general, you should focus on analyzing Werewolf Stock price patterns and their correlations with different microeconomic environments and drivers.
Werewolf Therapeutics Predictive Forecast Models
Werewolf Therapeutics' time-series forecasting models is one of many Werewolf Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Werewolf Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Werewolf Therapeutics
Checking the ongoing alerts about Werewolf Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Werewolf Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Werewolf Therapeutics generated a negative expected return over the last 90 days | |
| Werewolf Therapeutics has high historical volatility and very poor performance | |
| Werewolf Therapeutics may become a speculative penny stock | |
| Werewolf Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 19.94 M. Net Loss for the year was (37.37 M) with loss before overhead, payroll, taxes, and interest of (37.36 M). | |
| Werewolf Therapeutics currently holds about 145.71 M in cash with (32.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.93, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 73.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Daniel Hicklin of 295500 shares of Werewolf Therapeutics subject to Rule 16b-3 |
Check out Werewolf Therapeutics Backtesting, Werewolf Therapeutics Valuation, Werewolf Therapeutics Correlation, Werewolf Therapeutics Hype Analysis, Werewolf Therapeutics Volatility, Werewolf Therapeutics History as well as Werewolf Therapeutics Performance. For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Werewolf Therapeutics. If investors know Werewolf will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Werewolf Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share 0.082 | Quarterly Revenue Growth (0.86) | Return On Assets (0.26) | Return On Equity (0.62) |
The market value of Werewolf Therapeutics is measured differently than its book value, which is the value of Werewolf that is recorded on the company's balance sheet. Investors also form their own opinion of Werewolf Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Werewolf Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Werewolf Therapeutics' market value can be influenced by many factors that don't directly affect Werewolf Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Werewolf Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Werewolf Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Werewolf Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.